Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions

American Journal of Medicine

Volumn 126, Issue 3, 2013, Pages 192-199

  Schwartz, Bryan G ^a   Jackson, Graham ^b   Stecher, Vera J ^c   Campoli Richards, Deborah M ^d   Kloner, Robert A ^a,e  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

^d Clinical Content and Editorial Services   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Flow mediated dilation; Heart failure; Hypertension; Nitric oxide; Pulmonary; Vasodilation

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTERIAL STIFFNESS; ARTERY DIAMETER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; ERECTILE DYSFUNCTION; EXERCISE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; LUNG EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REPERFUSION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; ISCHEMIC PRECONDITIONING; PHOSPHODIESTERASE 5 INHIBITORS; VASODILATION;

EID: 84873630842     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.08.015     Document Type: Review

References (50)

1. B.G. Schwartz, C. Economides, G.S. Mayeda The endothelial cell in health and disease: its function, dysfunction, measurement and therapy Int J Impot Res 22 2010 77 90
2. C. Napoli, L.J. Ignarro Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases Arch Pharm Res 32 2009 1103 1108
3. C. Gazzaruso, S.B. Solerte, A. Pujia Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors J Am Coll Cardiol 51 2008 2040 2044
4. V.W. Liu, P.L. Huang Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice Cardiovasc Res 77 2008 19 29
5. A. Konstantinopoulos, K. Giannitsas, A. Athanasopoulos The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction Expert Opin Pharmacother 10 2009 155 160
6. A. Aversa, C. Vitale, M. Volterrani Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes Diabet Med 25 2008 37 44
7. G.M. Rosano, A. Aversa, C. Vitale Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk Eur Urol 47 2005 214 220
8. R.C. Kukreja, F. Salloum, A. Das Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications Vascul Pharmacol 42 2005 219 232
9. V.Q. Chau, F.N. Salloum, N.N. Hoke Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway Am J Physiol Heart Circ Physiol 300 2011 H2272 H2279
10. E. Mazo, S. Gamidov, V. Iremashvili The effect of vardenafil on endothelial function of brachial and cavernous arteries Int J Impot Res 18 2006 464 469
11. S.D. Katz, K. Balidemaj, S. Homma Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure J Am Coll Cardiol 36 2000 845 851
12. M. Kimura, Y. Higashi, K. Hara PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers Hypertension 41 2003 1106 1110
13. C. Vlachopoulos, D. Tsekoura, N. Alexopoulos Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction Am J Hypertens 17 2004 1040 1044
14. C. Desouza, A. Parulkar, D. Lumpkin Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes Diabetes Care 25 2002 1336 1339
15. L. Deyoung, E. Chung, J.R. Kovac Daily use of sildenafil improves endothelial function in men with type 2 diabetes J Androl 33 2012 176 180
16. A. Aversa, E. Greco, R. Bruzziches Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study Int J Impot Res 19 2007 200 207
17. F. Sommer, T. Klotz, U. Engelmann Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial Asian J Androl 9 2007 134 141
18. Y. Vardi, B. Appel, Y. Ofer Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study J Urol 182 2009 2850 2855
19. A. Behling, L.E. Rohde, F.C. Colombo Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial J Card Fail 14 2008 189 197
20. T.M. Attina, L.S. Malatino, S.R. Maxwell Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients J Hypertens 26 2008 501 507
21. B.A. Kaufmann, A.M. Bernheim, S. Kiencke Evidence supportive of impaired myocardial blood flow reserve at high altitude in subjects developing high-altitude pulmonary edema Am J Physiol Heart Circ Physiol 294 2008 H1651 H1657
22. H.A. Ghofrani, F. Reichenberger, M.G. Kohstall Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial Ann Intern Med 141 2004 169 177
23. J.W. Park, B. Leithauser, C. Mrowietz Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease Int J Impot Res 20 2008 150 156
24. J.W. Park, C. Mrowietz, N. Chung Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study Clin Hemorheol Microcirc 31 2004 173 183
25. K. Hirata, A. Adji, C. Vlachopoulos Effect of sildenafil on cardiac performance in patients with heart failure Am J Cardiol 96 2005 1436 1440
26. J.J. Oliver, V.P. Melville, D.J. Webb Effect of regular phosphodiesterase type 5 inhibition in hypertension Hypertension 48 2006 622 627
27. C. Vlachopoulos, K. Hirata, M.F. O'Rourke Effect of sildenafil on arterial stiffness and wave reflection Vasc Med 8 2003 243 248
28. K. Shigemura, S. Arakawa, S. Kamidono Effect of sildenafil on arterial stiffness, as assessed by pulse wave velocity, in patients with erectile dysfunction Int J Urol 13 2006 956 959
29. R.S. Schofield, D.G. Edwards, B.T. Schuler Vascular effects of sildenafil in hypertensive cardiac transplant recipients Am J Hypertens 16 2003 874 877
30. J.P.J. Halcox, K.R.A. Nour, G. Zalos The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia J Am Coll Cardiol 40 2002 1232 1240
31. T. Reffelmann, R.A. Kloner Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation Cardiovasc Res 59 2003 441 449
32. H.C. Herrmann, G. Chang, B.D. Klugherz Hemodynamic effects of sildenafil in men with severe coronary artery disease N Engl J Med 342 2000 1622 1626
33. N. Werner, S. Kosiol, T. Schiegl Circulating endothelial progenitor cells and cardiovascular outcomes N Engl J Med 353 2005 999 1007
34. C. Foresta, A. Ferlin, L. De Toni Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction Int J Impot Res 18 2006 484 488
35. C. Foresta, L. De Toni, A. Di Mambro The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression J Sex Med 6 2009 369 372
36. C. Foresta, A. Lana, A. Cabrelle PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans Int J Impot Res 17 2005 377 380
37. M. Bocchio, G. Desideri, P. Scarpelli Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage J Urol 171 2004 1601 1604
38. B.G. Schwartz, R.A. Kloner Coronary no reflow J Mol Cell Cardiol 52 2012 873 882
39. B.G. Schwartz, L.A. Levine, G. Comstock Cardiac uses of phosphodiesterase-5 inhibitors J Am Coll Cardiol 59 2012 9 15
40. G. Szabo, T. Radovits, G. Veres Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass Eur J Cardiothorac Surg 36 2009 657 664
41. M. Guazzi, M. Samaja, R. Arena Long-term use of sildenafil in the therapeutic management of heart failure J Am Coll Cardiol 50 2007 2136 2144
42. M. Guazzi, M. Casali, F. Berti Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients Clin Pharmacol Ther 83 2008 336 341
43. C. Mammi, D. Pastore, M.F. Lombardo Sildenafil reduces insulin-resistance in human endothelial cells PLoS ONE 6 2011 e14542
44. Y. Ishibashi, T. Matsui, M. Takeuchi Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP Clin Exp Med 11 2011 131 135
45. J.E. Ayala, D.P. Bracy, B.M. Julien Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice Diabetes 56 2007 1025 1033
46. F. Grover-Paez, G. Villegas Rivera, R. Guillen Ortiz Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes Diabetes Res Clin Pract 78 2007 136 140
47. B.R. Lindman, A. Zajarias, J.A. Madrazo Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis Circulation 125 2012 2353 2362
48. P.J. Kuhlencordt, R. Gyurko, F. Han Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice Circulation 104 2001 448 454
49. A. Giaid, D. Saleh Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 1995 214 221
50. L. Zhao, N.A. Mason, N.W. Morrell Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428